In patients with metabolic dysfunction-associated steatotic liver disease, there is increased risk for heart failure with preserved ejection fraction.

Dr Pandey shares key insights on dosing, monitoring, and patient education to sustain therapy and improve outcomes. Essential ...

"Our study shines a light on an important gap in how we detect HFpEF before the heart becomes irreversibly damaged," says Hai ...

For patients with chronic unexplained dyspnea seen in the outpatient setting, the optimal thresholds of plasma NT-proBNP currently used to diagnosis heart failure with preserved ejection fraction ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

The main results of the SUMMIT trial, reported last year, showed that tirzepatide—a dual glucose-dependent insulinotropic ...

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its subtypes, offering new hope for precision medicine in cardiology. A recent study ...

New study shows tirzepatide reduces LV mass and heart fat in obesity-related HFpEF, potentially improving heart failure outcomes.

温州医科大学药学院的研究人员在《Nature Communications》期刊上发表了题为 “FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice” 的论文。该研究在心力衰竭伴射血分数保留（HFpEF）领域具有重要意义，为理解 HFpEF ...

TX45 improved both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (“PH-HFpEF ...

The reason why is because the company still has the ongoing phase 2 APEX study, for starters, using TX45 to target these [PH-HFpEF] patients. Data from this particular mid-stage study is expected ...

尽管科学家们在HFrEF的治疗研究上取得了重大进展，但HFrEF所产生的并发症和死亡率仍然很高，此外，大多数已经展现出对HFrEF患者有益的药物在HFpEF患者中并未表现出类似的治疗效益，这或许就突出了开发针对这两种心力衰竭亚型的靶向性疗法的迫切需要 ...